Description
Glemont L (SP) Tablets 7’s
A specialized 7‑tablet pack of the fixed‑dose combination of Montelukast 10 mg and Levocetirizine 5 mg, formulated for the short-term management of both asthma and allergic rhinitis symptoms.
✅ Key Features
-
Dual-Action Relief: Montelukast helps reduce airway inflammation and bronchoconstriction, while Levocetirizine provides fast-acting control of allergy symptoms like sneezing, watery eyes, and nasal congestion.
-
Compact Special Pack (“SP”): Ideal for short therapy courses (e.g. seasonal allergies or episodic flare-ups).
-
Once-Daily Immediate-Release Tablet: Designed for convenience and consistent daily relief.
💊 Indications
-
Management of allergic rhinitis (seasonal or perennial)
-
Symptom relief in asthma, including exercise-induced bronchospasm
-
Combined allergy and respiratory conditions
📅 Dosage & Administration
-
Adults and adolescents: One tablet once daily, preferably in the evening, with or without food.
-
Tablets should be swallowed whole and not crushed or chewed.
⚠️ Contraindications & Precautions
-
Should not be used in individuals with known hypersensitivity to Montelukast, Levocetirizine, or related compounds.
-
Exercise caution in patients with severe kidney impairment (CrCl < 10 mL/min) and in those with lactose intolerance due to excipient content. My Health Box
-
Not suitable as a rescue treatment for acute asthma attacks; a fast-acting bronchodilator should be available.
-
Use cautiously during pregnancy or lactation—only if clearly essential and under medical supervision.
⚠️ Common Side Effects
-
Montelukast component: generally well tolerated; hypersomnia reported in rare cases.
-
Levocetirizine component: may cause somnolence, fatigue or mild asthenia in some users. Most reactions are mild to moderate.
🧾 Overview
The special pack (SP) of Glemont L Tablets 7’s is optimized for convenient short-course use, combining Montelukast and Levocetirizine in a simple once-daily tablet. It effectively addresses coexisting respiratory
Reviews
There are no reviews yet.